5-α Reductase Inhibitors and Prostate Cancer Mortality: A Population-Based Cohort Study in Canada

Advanced Prostate Cancer Consensus Conference (APCCC) shared a post on LinkedIn, about recent paper published in JAMA Network Open:

5-α Reductase Inhibitors and Prostate Cancer Mortality.

Authors: Robert J. Hamilton, Julian Chavarriaga, Najia Khurram, Cindy Lau, Jin Luo, Ning Liu, Maria Komisarenko, Girish Kulkarni, Christopher Wallis, David N. Juurlink, Neil Fleshner, Antonio Finelli.

”5-α Reductase Inhibitors and Prostate Cancer Mortality out on JAMA Network Open.

Population-based cohort study investigates whether the use of 5-alpha-reductase inhibitors (5-ARIs), commonly prescribed for benign prostatic hyperplasia (BPH) and known to reduce prostate cancer (PCa) risk by 25%, affects mortality in men diagnosed with clinically localized PCa.

Conducted in Canada, between 2003 and 2017, the study included 19,938 men aged 65 and older. Of these, 10.6% were 5-ARI users. After a median follow-up of nearly 9 years, the study found no significant association between prediagnostic 5-ARI use and either overall or PCa-specific mortality.

These findings provide reassurance regarding the long-term safety of 5-ARI use in patients with PCa.”

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn